Pfizer CEO Brags ‘Cancer Is The New Covid’ As He Introduces New mRNA Cancer-Jab Roll-Out
In a display of audacity that nearly defies belief, Pfizer's very own Albert Bourla unabashedly declared cancer as the next golden goose for the pharmaceutical leviathan, echoing a sentiment that would seem grotesque to the uninitiated.
"Oncology is our new Covid," Bourla proclaimed with a straight face in a dialogue with Fox Business, painting a future where battling cancer becomes as profitable as their pandemic-era escapades. With a tone dripping with pride for their past 'heroics' in saving the world from the clutches of Covid-19, Bourla positions Pfizer at the forefront of the next medical crusade, this time against cancer.
But here's where the plot thickens, as Bourla confidently asserts that Pfizer's arsenal of cancer drugs will miraculously elevate survival rates, a claim that raises eyebrows as much as it does questions.
The conversation with Fox Business subtly morphs into an almost dystopian narrative where Big Pharma's knight in shining armor pledges to conquer cancer, conveniently glossing over the swirling controversies and whispers in the corridors of science that link their flagship Covid vaccine to cancer itself.
It's a twist that would be comical if it weren't so tragically ironic; the very entity that positioned itself as humanity's savior against one plague is now gearing up to profit from another, amidst swirling allegations that their solution to the first may well be contributing to the second. In this bizarre reality where Big Pharma scripts the narrative, the line between savior and profiteer blurs, leaving the discerning observer to ponder the true cost of our salvation.
While the Covid vaccine is indicated to cause cancer, the recent push to chemically transgender more children is another possible source of new customers, as it has been documented that transgender drugs cause cancer as well.
The statements from the CEO only serve to confirm the company’s problem, reaction, solution business tactic, as it was reported months back that the firm had invested big into cancer drugs.
